Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Spinal Cord Injury Research Program

Investigator-Initiated Research Award

Funding Opportunity Number: W81XWH-09-SCIRP-IIRA

Table of Contents

I. FUNDING OPPORTUNITY DESCRIPTION .......................................................... 2
   A. Program Background ..................................................................................... 2
   B. Award Description ...................................................................................... 3
   C. Eligibility ..................................................................................................... 5
   D. Funding ........................................................................................................ 5
   E. Award Administration .................................................................................. 6
II. TIMELINE FOR SUBMISSION AND REVIEW ............................................... 6
III. SUBMISSION PROCESS ................................................................................ 6
    A. Step 1 – Pre-Application Components and Submission ................................ 6
    B. Step 2 – Application Components and Submission ..................................... 8
IV. INFORMATION FOR APPLICATION REVIEW .......................................... 10
    A. Application Review and Selection Overview .............................................. 10
    B. Review Criteria ......................................................................................... 11
V. ADMINISTRATIVE ACTIONS ....................................................................... 13
VI. CONTACT INFORMATION .......................................................................... 14
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Background

1. Program Objectives

The Spinal Cord Injury Research Program (SCIRP) was established in fiscal year 2009 (FY09) to promote research into regenerating/repairing damaged spinal cords and improving rehabilitation therapies that offer real promise for enhancing long-term care of wounded soldiers. The SCIRP focuses its funding on innovative projects that have the potential to make a significant impact on improving the function, wellness, and overall quality of life for military service members as well as their caregivers, families, and the American public. Approximately $35 million (M) of the FY09 supplemental appropriations bill, Public Law 110-329, was made available to support spinal cord injury (SCI) research. The Government reserves the right to increase or decrease the SCIRP funding of $35M to execute the program.

The FY09 SCIRP challenges the scientific community to design innovative research that will foster new directions for and address neglected issues in the field of SCI-focused research. Proposals involving multidisciplinary collaborations among academia, industry, the military services, the Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged. Though the SCIRP supports groundbreaking research, all projects must demonstrate solid judgment and rationale.

2. Areas of Encouragement

The FY09 SCIRP encourages proposals that specifically address the critical needs of the SCI community in the following areas:

- Neuro-protection and repair
- Rehabilitation and complications of chronic SCI
- Outcome measures to include development and validation

Several areas are of particular interest to the program; however, all areas may not be applicable to each mechanism. These areas include:

- The identification, refinement, and validation of outcome measures and devices to allow improved assessment of interventions in animal models and humans.
- A bio-physiological understanding of the mechanism of injury and repair throughout the progression of the injury from acute to subacute to chronic.
- Understanding the relationship between animal models and clinical/human application, including an understanding of the scaling issues between animals and humans as well as the pathobiological and behavioral relevance of animal models.
- Understanding and leveraging the clinical characteristics of injury and repair that can translate back to and guide priorities for basic research.
- Predictors of poor clinical outcomes and associated maladaptive plasticity.
- Comparative clinical trials that assess the differences between rehabilitation methods.
- Understanding the physiological basis (neuroplasticity) for rehabilitation therapies and evaluating whether there are quantitative benefits of activity-dependent rehabilitation training.
- Development and refinement of assistive and rehabilitation strategies and technologies to deliver improved functional capacity for people living with SCI.
- Research into advanced rehabilitation technologies including their contribution to neuroplasticity (e.g., tele-rehabilitation, simulation, virtual reality, functional electrical stimulation, exoskeleton movement systems, and robotics).
- Prevention of medical complications from SCI (e.g., cardiac disease, autonomic dysreflexia, spasticity, pain, skin care issues, bladder and bowel dysfunction, sexual dysfunction, and bone fractures).
- Utilization of existing clinical trials infrastructure and resources of established collaborations to enable rapid initiation of research that leverages available systems for structured data collection, analysis, and/or outcomes assessment.

B. Award Description

The Investigator-Initiated Research Award (IIRA) is intended to support studies that make an important contribution to SCI research and/or patient care. Projects should address an Area of Encouragement and be applicable to the health care needs of the military service members, their family members, and/or the U.S. veteran population. All applications must specifically and clearly address the military relevance of the proposed research. Collaboration with military researchers and clinicians is encouraged.

Research projects may focus on any phase of research from basic laboratory through translational research including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial. Observations that drive a research idea may be derived from laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patients and anecdotal data.

Proposals must include preliminary and/or published data relevant to the topic area and the proposed project.

Clinical trials are not allowed under this mechanism. Principal Investigators (PIs) wishing to apply for funding for a clinical trial focused on rehabilitative medicine should utilize the SCIRP Clinical Trial Award – Rehabilitation mechanism (for information about this mechanism, see http://cdmrp.army.mil). Refer to the Application Instructions & General Information, Appendix 6, for helpful information about distinguishing clinical trials and clinical research.

Use of Human Subjects and Human Biological Substances: All DOD-funded research involving human subjects and human biological substances must be reviewed and approved by the USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to local IRBs. The HRPO is mandated to comply with specific laws and
Directives governing all research involving human subjects that is conducted or supported by the DOD. These laws and directives are rigorous and detailed and will require information in addition to that supplied by the local review board. Allow a minimum of 6 months for regulatory review and approval processes for studies involving human subjects. Refer to the Application Instructions & General Information, Appendix 6, for additional information.

**Encouraged Department of Defense (DOD) Collaboration and Alignment:** Military relevance is a key feature of this program. Therefore, alignment with current DOD research and collaboration with military researchers and clinicians is encouraged. The following websites may be useful in identifying information about ongoing DOD areas of research interest within the FY09 SCI Areas of Encouragement.

- Defense Technical Information Center
  [http://www.dtic.mil](http://www.dtic.mil)
- Congressionally Directed Medical Research Programs
  [http://cdmrp.army.mil](http://cdmrp.army.mil)
- U.S. Army Medical Research and Materiel Command
  [https://mrmc.amedd.army.mil](https://mrmc.amedd.army.mil)
- Air Force Research Laboratory
- Navy and Marine Corps Public Health Center
- U.S. Department of Veterans Affairs, Office of Research and Development
  [www.research.va.gov](http://www.research.va.gov)
- Office of Naval Research
- U.S. Army Research Laboratory
  [http://www.arl.army.mil](http://www.arl.army.mil)
- U.S. Naval Research Laboratory
  [www.nrl.navy.mil](http://www.nrl.navy.mil)
- Defense Advanced Research Projects Agency
- U.S. Army Medical Research Acquisition Activity
  [http://www.usamrba.army.mil](http://www.usamrba.army.mil)
- Naval Health Research Center
- Office of the Under Secretary of Defense for Acquisition, Technology and Logistics

**Optional Qualified Collaborator(s):** The FY09 SCIRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and biotechnology/pharmaceutical industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the SCI field are also strongly encouraged. Collaborations that meet the criteria below will qualify for a higher level of funding as described in Section I.D.

For the application to qualify for the higher level of funding, the PI must submit a Statement of Collaboration that clearly identifies the collaborating investigator and addresses how each of the criteria below are met. Additionally, the collaborator must provide a letter of collaboration describing his/her involvement in the proposed work. It should be clear that the success of the project depends on the unique skills and contributions of each partner.
• The collaborator(s) must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.
  o A proposed project in which the collaborator(s) merely supplies tissue samples or access to patients will not meet the intent and will not be qualified for the higher level of funding.
• Either the PI or the collaborator(s) must have SCI research experience as demonstrated through publications and/or funding history.
• The collaborator(s) must be at or above the level of Assistant Professor (or equivalent).
• At least a 10% level of effort is required of the collaborator(s). Contribution of the collaborator should be reflected in the application’s budget.

C. Eligibility

Independent investigators at all academic levels (or equivalent) are eligible to submit applications. Refer to the Application Instructions & General Information, Appendix 1, for general eligibility information.

D. Funding

• The maximum period of performance is 3 years.
• The maximum allowable funding for the entire period of performance is $500,000 in direct costs ($750,000 in direct costs if requesting an Optional Qualified Collaborator).
• More cost-effective studies that do not request the full available funding amount are encouraged. The applicant may also request the entire maximum direct cost amount for a project that may be less than the maximum 3-year period of performance.
• Regardless of the period of performance proposed, the applicant may not exceed the maximum direct cost. In addition to the direct costs, indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Within the guidelines provided in the Application Instructions & General Information, funds can cover:

• Salary
• Research supplies
• Equipment
• Clinical costs (no clinical trials allowed)
• Travel between collaborating institutions
• Travel to scientific/technical meetings, including travel to one DOD-sponsored scientific meeting.

The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $6.4 of the $35M FY09 SCIRP appropriation to fund approximately eight IIAR
applications, depending on the quality and number of proposals received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent on the availability of Federal funds for this program.

E. Award Administration

Refer to the Application Instructions & General Information, Appendix 5, for general award administration information.

II. TIMELINE FOR SUBMISSION AND REVIEW

Submission is a two-step process consisting of (1) pre-application submission and (2) application submission. **Pre-application submission is a required first step.**

- **Pre-application Submission Deadline:** August 27, 2009, 5:00 p.m. Eastern Time (ET)
- **Invitations to Submit Full Proposals Sent:** No later than October 2009
- **Application Submission Deadline:** December 10, 2009, 11:59 p.m. ET
- **Scientific Peer Review:** January-February, 2010
- **Programmatic Review:** March 2010

Awards will be made approximately 4 to 6 months after receiving a funding notification letter, but no later than September 30, 2010.

III. SUBMISSION PROCESS

Submission is a two-step process consisting of (1) a pre-application submission through the CDMRP eReceipt system [https://cdmrp.org/](https://cdmrp.org/), and (2) an application submission through Grants.gov [http://www.grants.gov/](http://www.grants.gov/). Applications will not be accepted unless a PI has been invited. **Do not submit an application unless a letter of invitation has been received.**

PIs and organizations identified in the application submitted through Grants.gov should be the same as those identified in the pre-application. If there is a change in PI or organization after submission of the pre-application, the PI must contact the eReceipt help desk at help@cdmrp.org or 301-682-5507.

The Government reserves the right to reject duplicative applications submitted to different award mechanisms within the same program or to other CDMRP programs.

A. Step 1 – Pre-Application Components and Submission

**Pre-application submission is the required first step.** The pre-application consists of the components discussed below. All pre-application components must be submitted electronically through the CDMRP eReceipt system by 5:00 p.m. ET on the deadline date. Refer to the Application Instructions & General Information for detailed information.
• Proposal Information
• Proposal Contacts
• Collaborators and Conflicts of Interest (COI)

• Preproposal Narrative: The Preproposal Narrative has a two-page limit inclusive of figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, cartoons, and other information needed to judge the preproposal. The preproposal narrative must be outlined as follows:
  o Research Idea: State the ideas and reasoning on which proposed work is based.
  o Research Strategy: Concisely state the project’s objectives and specific aims.
  o Impact: State explicitly how the proposed work will have an impact on the understanding of SCI and/or amelioration of its consequences.
  o Innovation: State explicitly how the proposed work is innovative.
  o Military Relevance: Describe how the proposed work is applicable to the health care needs of military service members, their family members, and/or the U.S. veteran population.
  o Alignment with Areas of Encouragement: If applicable, explain how the proposed work addresses one or more of the FY09 SCIRP Areas of Encouragement.

• Pre-Application Supporting Documentation: The items to be included as supporting documentation for the pre-application are:
  o References: One-page limit.
  o Biographical Sketches: Include biographical sketches for the PI and other key collaborators.

Pre-Application Screening: Pre-applications will be screened by the SCIRP Integration Panel (IP), composed of scientists, clinicians, and consumer advocates. The pre-application screening criteria are as follows:

• Research Idea: Whether the described research demonstrates solid judgment and rationale for SCI research.

• Research Strategy: How well the specific aims support the research idea.

• Impact: How well the study addresses an important problem related to SCI. If successful, how the study will improve the understanding of SCI and/or amelioration of its consequences.

• Innovation: How the study is innovative in one or more ways including but not limited to concept or question, research methods or technologies, adaptations of existing methods or technologies, and clinical interventions.

• Military Relevance: How the proposed study may directly or indirectly benefit the identified military population, family member, or U.S. veteran, if successful.

• Alignment with Areas of Encouragement: If applicable, how well the proposed study addresses at least one of the FY09 SCIRP Areas of Encouragement.
B. Step 2 – Application Components and Submission

Application submissions will not be accepted unless the PI has been invited. Do not submit an application unless a letter of invitation has been received. Applications must be submitted electronically by the Authorized Organizational Representative (AOR) through Grants.gov (www.grants.gov).

Each application submission must include the completed application package of forms and attachments identified in www.grants.gov for this U.S. Army Medical Research Acquisition Activity (USAMRAA) Program Announcement/Funding Opportunity. In addition to the specific instructions below, please refer to the Application Instructions & General Information for detailed requirements of each component.

The package includes:

1. SF-424 (R&R) Application for Federal Assistance Form

2. Attachments Form
   - Attachment 1: Project Narrative (10-page limit)
     Describe the proposed project in detail using the outline below. The project narrative must include preliminary data that is relevant to SCI and the proposed project.
     - **Background:** Present the ideas and reasoning behind the proposed work. Cite relevant literature. Describe previous experience most pertinent to this project.
     - **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
     - **Specific Aims:** Concisely explain the project’s specific aims to be funded by this application. If the proposed work is part of a larger study, present only tasks that the DOD award would fund.
     - **Research Strategy:** Describe the study design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. Describe the statistical plan if appropriate for the research proposed. This award may not be used to conduct clinical trials.
   - Attachment 2: Supporting Documentation
     - References Cited
     - Acronyms and Symbol Definitions
     - Facilities & Other Resources
     - Description of Existing Equipment
- Publications and/or Patent Abstracts (five-document limit)
- Letters of Institutional Support (two-page limit per letter)
- If the PI is a practicing clinician, the institution must clearly demonstrate a commitment to the clinician’s research.
- Letters of Collaboration (if applicable, two-page limit per letter)
- Intellectual and Material Property Plan (if applicable)

- **Attachment 3: Technical Abstract (one-page limit)**
- **Attachment 4: Public Abstract (one-page limit)**
- **Attachment 5: Statement of Work (SOW, three-page limit)**
- **Attachment 6: Detailed Budget and Justification**
- **Attachment 7: Impact Statement (one-page limit)**

Describe the potential impact of this study on the field of research and/or patient care in SCI. Include an assessment of the likelihood that a successful outcome to the research project will lead to a practical application in patients. The following are examples of ways in which proposed studies, if successful may have an impact. Although not all inclusive, these examples are intended to help PIs frame the impact of the proposed research:

- Has the potential to advance the field of research in SCI.
- Has the potential to change the standard of care.
- Contributes to the development or validation of evidence-based policy or guidelines for patient evaluation and care.

- **Attachment 8: Innovation Statement (one-page limit)**

Summarize how the proposed work is innovative. Investigating the next logical step or incremental advancement on published data is not considered innovative. **Although not all-inclusive**, the following examples are ways in which the proposed work may be innovative and are intended to help PIs frame the innovative features:

- Study concept: Investigation of a novel idea and/or research question.
- Research method or technology: Use of novel research methods or new technologies, including technology development, to address a research question.
- Novel method or technology: Development of a novel method or technology for preventing, detecting, diagnosing, or treatment.
- Existing methods or technologies: Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.
Attachment 9: Statement of Collaboration (required if requesting higher level of funding)

If applying for the higher level of funding, the PI must submit a statement that identifies the collaborating investigator and addresses all criteria described in Section I.B. It should be clear that the success of the project depends on the unique skills and contributions of each partner.

Attachment 10: Military Relevance Statement (one-page limit)

Demonstrate how the proposed study is applicable to the health care needs and quality of life of military service members, their family members, and/or the U.S. veteran population. If active duty military, military families, or veteran population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed study, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., Armed Forces, their family members, and/or the U.S. veteran population).

Attachment 11: Approval for Access to Military and VA Populations (if applicable, one-page limit)

A letter of support, signed by the lowest ranking person with approval authority, should be included for studies involving active duty military, military families, or veterans; military-controlled study materials; databases; and/or restricted facilities (e.g., biological or chemical containment facilities).

Attachment 12: Federal Agency Financial Plan (if applicable)

Attachments 13-15: Subaward Detailed Budget and Justification (if applicable)

3. Research & Related Senior/Key Person Profile (Expanded)

- PI Biographical Sketch (four-page limit)
- PI Current/Pending Support
- Key Personnel Biographical Sketches (four-page limit each)
- Key Personnel Current/Pending Support

4. Research & Related Project/Performance Site Location(s) Form

IV. INFORMATION FOR APPLICATION REVIEW

A. Application Review and Selection Overview

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a scientific peer review of applications against established criteria for determining scientific merit. The second tier is a programmatic review that compares submissions to each other and recommends proposals for funding based on scientific merit, overall goals of the program, and specific intent of the award mechanism. Additional
information about the two-tier review process used by the CDMRP may be found at [http://cdmrp.army.mil/fundingprocess](http://cdmrp.army.mil/fundingprocess)

The peer review and programmatic review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each tier of review requires panelists to sign a non-disclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Institutional personnel and PIs are prohibited from contacting persons involved in the application review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the institution’s application. Violations by panelists or PIs that compromise the confidentiality of the peer review and programmatic review processes may also result in suspension or debarment of their employing institutions from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

The Government reserves the right to review all applications based on one or more of the required attachments or supporting documentation (e.g., Impact Statement, Military Relevance Statement, etc.).

**B. Review Criteria**

1. **Peer Review:** All applications will be evaluated according to the following criteria, which are listed in order of decreasing importance:

   - **Research Strategy and Feasibility (preliminary data are required)**
     - How well the preliminary data and scientific rationale supports the research project.
     - How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed and integrated into the project.
     - How well the PI acknowledges potential problems and addresses alternative approaches.

   - **Impact**
     - How the proposed study addresses a critical problem in SCI research or patient care.
     - How the proposed research will make original and important contributions toward the goal of advancing SCI research or patient care.

   - **Innovation**
     - How the research proposes new paradigms or challenges existing paradigms in one or more of the following ways: concept or question, research methods or technologies, adaptations of existing methods or technologies, and clinical interventions.
     - How the proposed research represents more than an incremental advance upon
published data.

○ How the potential gain justifies the perceived risk.

- **Personnel**
  ○ How the background and expertise of the PI and other key personnel are appropriate to accomplish the proposed work.
  ○ How the levels of effort by the PI and other key personnel are appropriate to ensure success of this project.
  ○ How the PI’s record of accomplishment demonstrates his/her ability to accomplish the proposed work.

○ **Optional Qualified Collaborator(s) (if applicable)**
  - Whether the collaborator’s experience, expertise, and involvement in the study significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement and how well the nature of the collaboration supports the research project.
  - Whether the collaborator(s) meets the criteria for an Optional Qualified Collaborator as verified by the Statement of Collaboration (i.e., the collaborator[s] possesses appropriate SCI research experience if the PI does not; the collaborator[s] is at or above the level of Assistant Professor [or equivalent]; the collaborator[s] is contributing at least 10% level of effort).

The following criteria will not be individually scored, but may impact the overall evaluation of the application:

- **Environment**
  ○ The appropriateness of the scientific environment for the proposed research.
  ○ How the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  ○ How the quality and extent of institutional support are appropriate for the proposed research.

- **Budget**
  ○ Whether the budget is appropriate for the proposed research and within the limitations of the award mechanism.

- **Application Presentation**
  ○ How the writing and components of the application influenced the review.

2. **Programmatic Review:** The following criteria are used by programmatic reviewers to make funding recommendations that maintain the program’s broad portfolio:

- Ratings and evaluations of the peer reviewers,
- Programmatic relevance,
• Program portfolio balance, with consideration of the Areas of Encouragement.
• Relative impact and innovation,
• Adherence to the intent of the award mechanism, and
• Military relevance

Scientifically sound proposals that best fulfill the above criteria and most effectively address the unique focus and goals of the program will be identified by IP members and recommended for funding to the Commanding General, U.S. Army Medical Research and Materiel Command. The highest scoring applications from the first tier of review are not automatically recommended for funding. All applications are carefully considered to ensure that the funds available are allocated to those proposals that best fulfill the goals and objectives of the program.

V. ADMINISTRATIVE ACTIONS

After receipt of pre-applications from eReceipt or applications from Grants.gov, the following administrative actions may occur.

A. Rejection

The following will result in administrative rejection of the pre-application:

• Preproposal Narrative exceeds page limit.
• Preproposal Narrative is missing.
• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

The following will result in administrative rejection of the application:

• Submission of an application for which a letter of invitation was not received.
• Project Narrative exceeds page limit.
• Project Narrative is missing.
• Budget is missing.
• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

B. Modifications

• Pages exceeding the specified limits will be removed for all documents other than the Project Narrative.
• Documents not requested will be removed.

NEW FOR FY09: Following the application deadline, you may be contacted by email from CDMRP with a request to provide certain missing supporting documents (excluding those listed directly above in Section A, Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date and time the
email was sent. Otherwise, the application will be peer reviewed without the missing documents.

C. Withdrawal

The following may result in administrative withdrawal of the application:

- The proposed research is or contains a clinical trial.
- FY09 IP member(s) is found to be involved in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY09 IP members may be found at [http://cdmrp.army.mil/09scirpppanel](http://cdmrp.army.mil/09scirpppanel)
- Submission of the same research project to different award mechanisms within the same program or to other CDMRP programs.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate scientific peer and programmatic review.
- Direct costs as shown on the detailed budget form exceed the maximum allowed by the award mechanism.
- Inclusion of URLs, with the exception of links to published references.
- The PI does not meet the eligibility criteria as described in this Program Announcement/Funding Opportunity.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be requested to provide the findings of the investigation to the USAMRAA Contracting/Grants Officer for a determination of the final disposition of the application.

VI. CONTACT INFORMATION

A. Program Announcement/Funding Opportunity, application format, or required documentation: To view all funding opportunities offered by the CDMRP, perform a Grants.gov basic search using the CFDA Number 12.420. Submit questions as early as possible. Response times will vary depending upon the volume of inquiries. Every effort will be made to answer questions within 5 working days.

   Phone: 301-619-7079
   Fax: 301-619-7792
   Email: cdmrp.pa@amedd.army.mil
B. **eReceipt system**: Questions related to pre-application components through the CDMRP eReceipt system should be directed to the eReceipt help desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.

   Phone: 301-682-5507  
   Website: [https://cdmrp.org](https://cdmrp.org)  
   Email: help@cdmrp.org

C. **Grants.gov contacts**: Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov help desk, which is available Monday through Friday, 7:00 a.m. to 9:00 p.m. ET. Deadlines for application submission are 11:59 p.m. ET on the deadline date. Please note that the CDMRP help desk is unable to answer questions about Grants.gov submissions.

   Phone: 800-518-4726  
   Email: support@grants.gov

*Grants.gov will notify PIs of changes made to this Program Announcement/Funding Opportunity and/or application package ONLY if the PI subscribes to the mailing list by clicking on the “send me change notification emails” link on the Opportunity Synopsis page for this announcement. If the PI does not subscribe and the application package is updated or changed, the original version of the application package may not be accepted.*